FDA grants de novo clearance to Bluegrass Vascular for Surfacer system
Ngày 18/02/2020 09:03 | Lượt xem: 1353

Bluegrass Vascular Technologies (Bluegrass Vascular) announced today that the US Food and Drug Administration (FDA) has granted a de novoclassification order for its Surfacer Inside-Out access catheter system. The Surfacer system is intended to obtain central venous access to facilitate catheter insertion into the central venous system for patients with upper body venous occlusions or other conditions that preclude central venous access by conventional methods. The Surfacer system employs a novel Inside-Out approach.

“The Surfacer system offers a safe and effective approach to reliably preserve and restore critical upper body vascular access sites,” stated Mahmood Razavi, interventional radiologist at St. Joseph Hospital in Orange, USA and lead principal investigator of the SAVE-US (Surfacer system to facilitate access in venous Occlusions—United States) IDE study. “This is an unmet clinical need for patients who require life-saving therapies, such as dialysis, and who have limited options due to venous obstructions.”

The Surfacer system is the first FDA cleared medical device to facilitate upper body central venous access in patients with venous obstructions or other conditions that preclude access by conventional methods. Approval is based on the results of the SAVE-US trial. Of the thirty enrolled patients, 90% met both the primary and secondary efficacy endpoints despite a complex patient population comprised largely of Type 3 and 4 obstructions (3 or more obstructed vessels). No device related adverse events were reported, confirming the safety and performance of the Surfacer system.

“Thoracic central venous obstruction (TCVO) is a costly problem associated with increased patient morbidity and reduced quality of life,” stated Bart Dolmatch, interventional radiologist at The Palo Alto Medical Foundation (Palo Alto, USA). “We have recently published reporting standards that create a common language for understanding and describing signs, symptoms, functional impairment, and anatomy of TCVO. BVT incorporated elements of these reporting standards into the SAVE-US trial, demonstrating the clinical impact of the Surfacer system. Now that it has been FDA cleared, the Surfacer will be part of the treatment algorithm for my patients with TCVO.”

Thoracic central venous obstruction occurs in roughly 40% of patients where haemodialysis is performed via a central venous catheter. While permanent arteriovenous fistulas are the preferred form of vascular access for haemodialysis patients, central venous catheters continue to serve as an important bridge to securing long-term access for life-saving haemodialysis treatment. The current approach for most patients with central venous obstructions is to use an alternative vein, which reduces the ability to place and mature a functioning fistula, resulting in increased catheter days and costs.

Source VascularNews

Duc Tin Clinic

Print Chia sẽ qua facebook bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua google bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua twitter bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua MySpace bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua LinkedIn bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua stumbleupon bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua icio bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua digg bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua yahoo bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua yahoo bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua yahoo bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system Chia sẽ qua yahoo bài: FDA grants de novo clearance to Bluegrass Vascular for Surfacer system

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP